Photo: elderly people in slofania were vaccinated with the new crown vaccine on the 27th. /Associated Press
[Ta Kung Pao] according to BBC and Agence France Presse, the European Drug Administration (EMA) decided on the 29th to approve the new crown vaccine jointly developed by British Pharmaceutical Company AstraZeneca and Oxford University to inject people over the age of 18. Germany previously said that due to insufficient data, it would not recommend the use of AstraZeneca vaccine for the elderly over 65 years old.
This is the third new vaccine approved for use in the European Union after Pfizer / biontech and Modena vaccines.
The German government said in a statement on the 28th that the German vaccine Commission (STIKO) currently lacks sufficient data to assess the effectiveness of the AstraZeneca vaccine for people aged 65 or above, so it is recommended that only people aged 18 to 64 be vaccinated.
In addition, earlier this week, two German media reported that the effective rates of AstraZeneca vaccine for the elderly were less than 10% and 8% respectively, which was later accused of rumors.
Although many countries have approved the vaccination of people over the age of 18, only 12% of the participants in the clinical trial are over 55 years old and they joined later, so there is not enough time to observe whether their prevalence rate is lower than that of the control group without vaccination.
British Prime Minister Johnson and England’s Department of public health (PHE) retorted that the AstraZeneca vaccine can produce a high degree of protection, especially for severe cases, ignoring the German proposal. AstraZeneca also said that clinical trial data have provided sufficient support for the efficiency of the elderly aged 65 or above.